Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.31 |
| ▸ | APEX1 | P27695 | 1/20 | 0.31 |
| ▸ | RECQL | P46063 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7663419 | 1.00 | POLB (0.35) | POLBALDH1A1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL19944700 | 0.85 | ALDH1A1 (0.38) | POLBALDH1A1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL10485411 | 0.83 | ALDH1A1 (0.41) | POLBALDH1A1L3MBTL1RECQLTDP1 | |
| SCHEMBL7360243 | 0.83 | ALDH1A1 (0.41) | POLBALDH1A1L3MBTL1RECQLTDP1 | |
| SCHEMBL1218407 | 0.83 | ALDH1A1 (0.41) | POLBALDH1A1L3MBTL1RECQLTDP1 | |
| SCHEMBL5406558 | 0.73 | — | — | |
| SCHEMBL5400982 | 0.73 | — | — | |
| SCHEMBL14566116 | 0.72 | ALDH1A1 (0.34) | ALDH1A1L3MBTL1RECQLTDP1KMT2A | |
| SCHEMBL10029224 | 0.70 | TDP1 (0.48) | POLBALDH1A1L3MBTL1APEX1RECQL | |
| SCHEMBL2512784 | 0.70 | TDP1 (0.48) | POLBALDH1A1L3MBTL1APEX1RECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100324305-A1 | PRODUCTION METHOD OF POLYCYCLIC LACTAMS | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-12-23 | — | — | US | disclosed |
| US-20090118519-A1 | Production Method of Polycyclic Lactams | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2009-05-07 | — | — | US | disclosed |
| EP-2014647-A1 | PROCESS FOR PRODUCING POLYCYCLIC LACTAM | Sumitomo Chemical Company, Limited (JP) | 2009-01-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118519-A1 | Production Method of Polycyclic Lactams | MRPL21, COASY, ASNS | POLB 1258/4885ALDH1A1 1979/4885CYP1A2 53/4885 |
| US-20100324305-A1 | PRODUCTION METHOD OF POLYCYCLIC LACTAMS | COASY, MRPL21, ASNS | POLB 1295/4885ALDH1A1 1821/4885CYP1A2 38/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.